Substance P Receptor Antagonists to Inhibit Tau Hyperphosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic interventions to prevent and treat chronic traumatic encephalopathy (CTE), a neurodegenerative disorder resulting from repeated concussions, characterized by the accumulation of hyperphosphorylated tau protein leading to neuronal dysfunction and psychiatric and behavioral disturbances, with no definitive diagnostic tests and limited understanding of long-term effects in amateur athletes and military personnel.
Innovation Solution
Administering a substance P receptor antagonist to inhibit tau hyperphosphorylation, thereby ameliorating the effects of CTE and related conditions by reducing the accumulation of hyperphosphorylated tau protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated concussions occur in athletes and military personnel, then the risk of developing CTE increases, but there is no definitive diagnostic test and limited understanding of long-term effects
Solution Approach 1:
The patent introduces substance P as an intermediary molecule that mediates the harmful effects of repeated concussions. By blocking substance P receptors with antagonists, the patent creates a therapeutic intervention point that can prevent CTE development without requiring definitive diagnostic tests, thus resolving the contradiction between needing reliable diagnosis and lacking understanding of long-term effects.
Solution Approach 2:
The patent applies preliminary action by administering substance P receptor antagonists before CTE fully develops. This preventive approach allows intervention based on risk factors (repeated concussions) rather than waiting for definitive diagnostic confirmation, addressing the limitation in diagnostic accuracy while preventing the disease before it manifests.
2Reliability
If substance P receptor antagonists are administered to inhibit tau hyperphosphorylation, then CTE progression is delayed, but the mechanism is not fully understood
Solution Approach 1:
The patent extracts the critical harmful function of substance P from the complex pathway of concussion-induced tau hyperphosphorylation. By isolating substance P as the key mediator and using receptor antagonists to block its action, the patent achieves therapeutic effectiveness without needing to fully understand every step of the underlying mechanism, thus resolving the contradiction between therapeutic reliability and mechanism understanding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Substance P receptor antagonists effectively prevent and treat CTE by inhibiting tau hyperphosphorylation, improving neurological and psychiatric symptoms, and potentially delaying the progression of the disease.
Implementation Method 1
substance P initiates tauhyperphosphorylation. It is prepared herein that substance P receptor antagonists are effective in reducing tauhyperphosphorylation thereby ameliorating the effects of CTE and related conditions
Data Source
AI summary
The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy.